Company to Hold Update Conference Call Today, August 16, 2013 at 10:00 a.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it has received positive survival results from interim preclinical tests for the Company's compound, RE-024, for the treatment of the
Retrophin Expands Management Team with Appointment of Steven R. Eby, R.Ph as Vice President, Global Strategy and Program Management NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. ( RTRX ), a pharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic
Retrophin Names Marc L. Panoff as Chief Financial Officer New York, NY (May 8, 2013) – Retrophin, Inc. (OTCQB: RTRX) today announced that it has named Marc L. Panoff, CPA, MBA as Chief Financial Officer and Chief Accounting Officer, effective May 20.
New York, NY (March 11, 2013) – Retrophin, Inc. (OTCQB: RTRX), a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options, today announced positive results